Keywords : ECS
Cannabinoids in Inflammatory Modulation of Allergic Respiratory Disorders and its Pharmacotherapeutic Approaches to central Respiratory disorders
European Journal of Molecular & Clinical Medicine,
2023, Volume 10, Issue 1, Pages 2548-2554
The study has clearly provided an idea of anti inflammatory responses of Cannabinoids against respiratory disorders. In that case, asthma can be considered as one of the major diseases and most of the individuals have been suffering from it. In that case, “human endocannabinoid system” can be considered as one of the complicated structures that are mainly responsible for producing signals. Therefore, the entire system of ECS includes ligand, enzymes, synthesis process and degradation. Cannabinoids can be obtained from the plant Cannabis Sativa plant. On the other hand, cannabinoids have the anti-inflammatory properties which can exacerbate the activation of CB2 signalling pathways. The study also demonstrates the derivative substances of cannabinoids has involved the inflammation process and also focuses on the immune responses. In this study, there were mainly two types of receptors mentioned and both of them belong from the G protein family. CB2 cells mainly activate and release proinflammatory mediators, which mainly act on the respiratory inflammation and also help in reducing the impact. In contrast, the activation of CB1 receptors directly impacts the bronchial nerve endings and it can be taken as a positive aspect for treating asthma.